Cognition Therapeutics Inc (CGTX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.16
• Market Cap: $91.81M
• EPS: $-0.47
• 52-Week High: $3.83
• 52-Week Low: $0.22

Market Sentiment

Cognition Therapeutics Inc currently has a Bullish sentiment score of 0.39.

About Cognition Therapeutics Inc

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Purchase, New York, dedicated to pioneering small molecule therapies for age-related neurodegenerative diseases and retinal disorders. With a robust focus on enhancing cognitive health and vision in the aging population, the company is actively advancing its innovative pipeline through cutting-edge research and development initiatives. Cognition Therapeutics's proprietary drug design capabilities posit...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Cognition Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CGTX pay dividends?

Cognition Therapeutics Inc (CGTX) does not currently pay a regular dividend.

What is CGTX's market cap?

Cognition Therapeutics Inc (CGTX) has a market capitalization of $91.81M with a current stock price of $1.16.